Sue & Bill Gross Stem Cell Center, 845 Health Science Road, UC Irvine, Irvine, CA 92697-1705, USA.
Regen Med. 2011 May;6(3):367-406. doi: 10.2217/rme.11.22.
There is potential for a variety of stem cell populations to mediate repair in the diseased or injured CNS; in some cases, this theoretical possibility has already transitioned to clinical safety testing. However, careful consideration of preclinical animal models is essential to provide an appropriate assessment of stem cell safety and efficacy, as well as the basic biological mechanisms of stem cell action. This article examines the lessons learned from early tissue, organ and hematopoietic grafting, the early assumptions of the stem cell and CNS fields with regard to immunoprivilege, and the history of success in stem cell transplantation into the CNS. Finally, we discuss strategies in the selection of animal models to maximize the predictive validity of preclinical safety and efficacy studies.
各种干细胞群体有可能介导病变或受损中枢神经系统的修复;在某些情况下,这种理论上的可能性已经过渡到临床安全性测试。然而,仔细考虑临床前动物模型对于适当评估干细胞的安全性和有效性以及干细胞作用的基本生物学机制至关重要。本文探讨了从早期组织、器官和造血移植中吸取的教训,干细胞和中枢神经系统领域关于免疫豁免的早期假设,以及将干细胞移植到中枢神经系统中取得成功的历史。最后,我们讨论了选择动物模型的策略,以最大限度地提高临床前安全性和有效性研究的预测有效性。